Livzon Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 1/6

Livzon Pharmaceutical Group zal naar verwachting groeien in winst en omzet met respectievelijk 10.2% en 5.6% per jaar. De winst per aandeel zal naar verwachting groeien met 10% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.1% zijn.

Belangrijke informatie

10.2%

Groei van de winst

10.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.8%
Inkomstengroei	5.6%
Toekomstig rendement op eigen vermogen	16.1%
Dekking van analisten	Good
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Recent updates

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Aug 30

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Aug 09

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Jul 02

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

Winst- en omzetgroeiprognoses

SZSE:000513 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	13,478	2,529	N/A	3,746	6
12/31/2025	12,656	2,274	N/A	2,064	7
12/31/2024	12,073	2,052	N/A	4,563	7
9/30/2024	11,857	2,025	2,673	3,344	N/A
6/30/2024	12,022	1,990	2,860	3,552	N/A
3/31/2024	12,260	1,980	3,044	3,873	N/A
12/31/2023	12,430	1,954	2,428	3,249	N/A
9/30/2023	12,796	2,004	2,433	3,137	N/A
6/30/2023	13,017	2,026	1,827	2,574	N/A
3/31/2023	12,564	1,938	1,477	2,362	N/A
12/31/2022	12,630	1,909	1,833	2,773	N/A
9/30/2022	12,183	1,830	1,152	2,445	N/A
6/30/2022	12,131	1,731	1,236	2,654	N/A
3/31/2022	12,193	1,809	833	2,098	N/A
1/1/2022	12,064	1,776	593	1,902	N/A
9/30/2021	11,964	1,746	905	1,948	N/A
6/30/2021	11,661	1,773	1,036	1,962	N/A
3/31/2021	11,365	1,835	1,507	2,313	N/A
1/1/2021	10,520	1,715	1,514	2,161	N/A
9/30/2020	10,015	1,685	1,342	1,857	N/A
6/30/2020	9,541	1,569	1,272	1,682	N/A
3/31/2020	9,282	1,309	1,236	1,649	N/A
1/1/2020	9,385	1,303	1,369	1,767	N/A
9/30/2019	9,314	1,182	1,685	2,069	N/A
6/30/2019	9,235	1,188	1,830	2,244	N/A
3/31/2019	9,099	1,128	1,131	1,540	N/A
12/31/2018	8,861	1,082	793	1,268	N/A
9/30/2018	8,851	1,123	531	1,015	N/A
6/30/2018	8,821	4,558	N/A	850	N/A
3/31/2018	8,774	4,501	N/A	1,266	N/A
1/1/2018	8,531	4,429	N/A	1,316	N/A
9/30/2017	8,450	4,416	N/A	1,324	N/A
6/30/2017	8,142	879	N/A	1,419	N/A
3/31/2017	8,032	829	N/A	1,399	N/A
12/31/2016	7,652	784	N/A	1,279	N/A
9/30/2016	7,458	742	N/A	1,240	N/A
6/30/2016	7,289	691	N/A	1,002	N/A
3/31/2016	6,813	670	N/A	990	N/A
12/31/2015	6,621	623	N/A	928	N/A
9/30/2015	6,311	588	N/A	894	N/A
6/30/2015	6,031	566	N/A	748	N/A
3/31/2015	5,869	555	N/A	623	N/A
12/31/2014	5,544	516	N/A	717	N/A
9/30/2014	5,506	532	N/A	482	N/A
6/30/2014	5,085	519	N/A	458	N/A
3/31/2014	4,791	484	N/A	561	N/A
12/31/2013	4,619	488	N/A	440	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 000513 ( 10.2% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 000513 ( 10.2% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 000513 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 000513 ( 5.6% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.9% per jaar).

Hoge groei-inkomsten: De omzet van 000513 ( 5.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 000513 zal naar verwachting over 3 jaar laag zijn ( 16.1 %).

Livzon Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased to CN¥42.19

Price target raised to CN¥51.22

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Now 21% undervalued after recent price drop

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥1.35

Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations